{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:15:29Z","timestamp":1792613729352,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Chemotherapy-induced peripheral neuropathy (CIPN), one of the most common and severe adverse effects of chemotherapy, is associated with worse quality of life among survivors of ovarian cancer. Currently, there is no effective treatment for CIPN.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the effect of a 6-month aerobic exercise intervention vs attention-control on CIPN among women treated for ovarian cancer in the Women\u2019s Activity and Lifestyle Study in Connecticut (WALC) to provide evidence to inform the guidelines and recommendations for prevention or treatment of CIPN.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prespecified secondary analysis evaluated the Women\u2019s Activity and Lifestyle Study in Connecticut (WALC), a multicentered, open-label, population-based, phase 3 randomized clinical trial of an aerobic exercise intervention vs attention control for CIPN in patients who were diagnosed with ovarian cancer. Only WALC participants who received chemotherapy were included in this analysis. Participants were randomized 1:1 to either a 6-month aerobic exercise intervention or to attention control. All analyses were conducted between September 2022 and January 2023.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The exercise intervention consisted of home-based moderate-intensity aerobic exercise facilitated by weekly telephone counseling from an American College of Sports Medicine\/American Cancer Society\u2013certified cancer exercise trainer. Attention control involved weekly health education telephone calls from a WALC staff member.<\/jats:p><\/jats:sec>Main Outcomes and Measure<\/jats:title>Change in CIPN was the primary outcome in this secondary analysis. This outcome was represented by CIPN severity, which was self-measured by participants at baseline and 6 months using the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group\u2013Neurotoxicity scale, with a score range of 0 to 44. A mixed-effects model was used to assess the 6-month change in CIPN between the exercise intervention and attention control arms.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 134 participants (all females; mean [SD] age, 57.5 [8.3] years) included in the analysis, 69 were in the exercise intervention arm and 65 were in the attention control arm. The mean (SD) time since diagnosis was 1.7 (1.0) years. The mean (SD) baseline CIPN scores were 8.1 (5.6) in the exercise intervention arm and 8.8 (7.9) in the attention control arm (P<\/jats:italic>\u2009=\u2009.56). At 6 months, the self-reported CIPN score was reduced by 1.3 (95% CI, \u22122.3 to \u22120.2) points in the exercise intervention arm compared with an increase of 0.4 (95% CI, \u22120.8 to 1.5) points in the attention control arm. The between-group difference was \u22121.6 (95% CI, \u22123.1 to \u22120.2) points. The point estimate was larger among the 127 patients with CIPN symptoms at enrollment (\u22122.0; 95% CI, \u22123.6 to \u22120.5 points).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings of this secondary analysis of the WALC trial indicate that a 6-month aerobic exercise intervention vs attention control significantly improved self-reported CIPN among patients who were treated for ovarian cancer. While replication of the findings in other studies is warranted, incorporating referrals to exercise programs into standard oncology care could reduce CIPN symptoms and increase quality of life in patients with ovarian cancer.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02107066<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.26463","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T15:00:51Z","timestamp":1690902051000},"page":"e2326463","source":"Crossref","is-referenced-by-count":37,"title":["Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Anlan","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Cartmel","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"},{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda T.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Harrigan","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Ligibel","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gogoi","sequence":"additional","affiliation":[{"name":"Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Esserman","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda L.","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"},{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah M.","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut"},{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"1","key":"zoi230766r1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.v73.1","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi230766r2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018.","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi230766r3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-9966-31-14","article-title":"Therapeutic strategies in epithelial ovarian cancer.","volume":"31","author":"Kim","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"zoi230766r4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.","volume":"12","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"zoi230766r5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with pre-existing neuropathy.","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"zoi230766r6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11910-008-0010-5","article-title":"Chemotherapy-induced peripheral neuropathy.","volume":"8","author":"Malik","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"zoi230766r7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jamaoncol.2018.6771","article-title":"Chemotherapy-induced peripheral neuropathy.","volume":"5","author":"Brown","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi230766r8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/bjc.2011.256","article-title":"Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.","volume":"105","author":"Lee","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"zoi230766r9","first-page":"696","article-title":"The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment.","volume":"37","author":"Jing","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"zoi230766r10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ijgo.v149.3","article-title":"Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.","volume":"149","author":"Jin","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"issue":"12","key":"zoi230766r11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"3","key":"zoi230766r12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ygyno.2014.09.016","article-title":"Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry.","volume":"135","author":"Ezendam","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"28","key":"zoi230766r13","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update.","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230766r14","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(16)30573-3","article-title":"Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA.","volume":"18","author":"Mayer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi230766r15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2018.03.052","article-title":"Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study.","volume":"149","author":"Bonhof","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi230766r16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi230766r17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi230766r18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2014.01.030","article-title":"Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).","volume":"133","author":"Au-Yeung","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"6","key":"zoi230766r19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamaoncol.2015.1796","article-title":"Impact of chemotherapy dosing on ovarian cancer survival according to body mass index.","volume":"1","author":"Bandera","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi230766r20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/0284186X.2015.1054950","article-title":"Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.","volume":"55","author":"Anuradha","year":"2016","journal-title":"Acta Oncol"},{"issue":"5","key":"zoi230766r21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer.","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"zoi230766r22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2018.07.021","article-title":"Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology\/Gynecologic Oncology Group study.","volume":"151","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"zoi230766r23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206913","article-title":"Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.","volume":"13","author":"Starbuck","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"zoi230766r24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/IGC.0b013e31819902ec","article-title":"Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning.","volume":"19","author":"Stevinson","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"zoi230766r25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230766r26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00520-017-3875-5","article-title":"Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial.","volume":"26","author":"Zimmer","year":"2018","journal-title":"Support Care Cancer"},{"issue":"6","key":"zoi230766r27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.clbc.2019.05.013","article-title":"Effect of exercise on taxane chemotherapy-induced peripheral neuropathy in women with breast cancer: a randomized controlled trial.","volume":"19","author":"Bland","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"zoi230766r28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1545968319899918","article-title":"An exploratory randomized trial of physical therapy for the treatment of chemotherapy-induced peripheral neuropathy.","volume":"34","author":"Andersen Hammond","year":"2020","journal-title":"Neurorehabil Neural Repair"},{"key":"zoi230766r29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jbmt.2021.07.013","article-title":"Effects of foam pad balance exercises on cancer patients undergoing chemotherapy: a randomized control trial.","volume":"28","author":"Saraboon","year":"2021","journal-title":"J Bodyw Mov Ther"},{"issue":"5","key":"zoi230766r30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1159\/000442253","article-title":"Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial.","volume":"62","author":"Schwenk","year":"2016","journal-title":"Gerontology"},{"issue":"1","key":"zoi230766r31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12885-019-5522-7","article-title":"It\u2019s never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial.","volume":"19","author":"Kneis","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"zoi230766r32","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00520-018-4531-4","article-title":"Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial.","volume":"27","author":"Streckmann","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"zoi230766r33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients.","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs"},{"issue":"7","key":"zoi230766r34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41416-021-01471-1","article-title":"Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial.","volume":"125","author":"M\u00fcller","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi230766r35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00520-017-4013-0","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi230766r36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11764-022-01182-3","article-title":"Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.","volume":"17","author":"Guo","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"12","key":"zoi230766r37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx072","article-title":"Randomized trial of exercise on quality of life in women with ovarian cancer: Women\u2019s Activity and Lifestyle Study in Connecticut (WALC).","volume":"109","author":"Zhou","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi230766r38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2337\/diacare.13.4.401","article-title":"Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians.","volume":"13","author":"Kriska","year":"1990","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi230766r39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12955-020-01493-y","article-title":"Psychometric testing of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (FACT\/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.","volume":"18","author":"Cheng","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"zoi230766r40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/psych.2001.52.issue-1","article-title":"Social cognitive theory: an agentic perspective.","volume":"52","author":"Bandura","year":"2001","journal-title":"Annu Rev Psychol"},{"key":"zoi230766r41","doi-asserted-by":"crossref","DOI":"10.1002\/9781119513469","author":"Fitzmaurice","year":"2011","journal-title":"Applied Longitudinal Analysis"},{"key":"zoi230766r42","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-022-01207-x","article-title":"Effect of exercise on body composition among women with ovarian cancer.","author":"Cao","year":"2022","journal-title":"J Cancer Surviv"},{"issue":"2","key":"zoi230766r43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11764-022-01325-6","article-title":"Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivors.","volume":"17","author":"Cao","year":"2023","journal-title":"J Cancer Surviv"},{"key":"zoi230766r44","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3389\/fpsyg.2015.01890","article-title":"Neuromodulation of aerobic exercise-a review.","volume":"6","author":"Heijnen","year":"2016","journal-title":"Front Psychol"},{"issue":"5","key":"zoi230766r45","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/cancers14051224","article-title":"Mechanisms, mediators, and moderators of the effects of exercise on chemotherapy-induced peripheral neuropathy.","volume":"14","author":"Chung","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"zoi230766r46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3322\/caac.v72.3","article-title":"American Cancer Society Nutrition and Physical Activity Guideline for cancer survivors.","volume":"72","author":"Rock","year":"2022","journal-title":"CA Cancer J Clin"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2807806\/cao_2023_oi_230766_1689968934.16238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T15:00:54Z","timestamp":1690902054000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2807806"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26463","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}